Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS - Get Free Report) Director Todd Davis purchased 35,948 shares of the company's stock in a transaction on Thursday, June 11th. The shares were purchased at an average price of $27.82 per share, for a total transaction of $1,000,073.36. Following the purchase, the director owned 75,834 shares in the company, valued at approximately $2,109,701.88. The trade was a 90.13% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Pelthos Therapeutics Stock Performance
Pelthos Therapeutics stock opened at $26.50 on Tuesday. The company has a current ratio of 2.79, a quick ratio of 1.86 and a debt-to-equity ratio of 1.41. The company's 50-day moving average price is $25.22. The stock has a market cap of $92.22 million, a P/E ratio of -1.28 and a beta of 3.17. Pelthos Therapeutics Inc. has a fifty-two week low of $11.20 and a fifty-two week high of $54.29.
Pelthos Therapeutics (NYSEAMERICAN:PTHS - Get Free Report) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($3.09) earnings per share for the quarter. The business had revenue of $10.91 million during the quarter. As a group, analysts predict that Pelthos Therapeutics Inc. will post -11.7 EPS for the current fiscal year.
Hedge Funds Weigh In On Pelthos Therapeutics
Large investors have recently bought and sold shares of the business. Persistent Asset Partners Ltd raised its holdings in Pelthos Therapeutics by 150.0% in the 4th quarter. Persistent Asset Partners Ltd now owns 6,007 shares of the company's stock worth $186,000 after purchasing an additional 3,604 shares during the period. Pale Fire Capital SE raised its holdings in Pelthos Therapeutics by 59.5% in the 1st quarter. Pale Fire Capital SE now owns 12,919 shares of the company's stock worth $271,000 after purchasing an additional 4,819 shares during the period. Millennium Management LLC acquired a new position in Pelthos Therapeutics in the 4th quarter worth about $343,000. Geode Capital Management LLC raised its holdings in shares of Pelthos Therapeutics by 31.9% during the fourth quarter. Geode Capital Management LLC now owns 13,625 shares of the company's stock valued at $422,000 after acquiring an additional 3,295 shares during the last quarter. Finally, Knott David M Jr raised its holdings in shares of Pelthos Therapeutics by 9.3% during the first quarter. Knott David M Jr now owns 21,073 shares of the company's stock valued at $443,000 after acquiring an additional 1,792 shares during the last quarter. Institutional investors and hedge funds own 77.96% of the company's stock.
Analyst Upgrades and Downgrades
Several research firms have weighed in on PTHS. Oppenheimer boosted their price target on Pelthos Therapeutics from $62.00 to $66.00 and gave the company an "outperform" rating in a research note on Friday, May 15th. Roth Mkm dropped their price target on Pelthos Therapeutics from $57.00 to $55.00 and set a "buy" rating on the stock in a research note on Thursday, February 26th. Cantor Fitzgerald began coverage on Pelthos Therapeutics in a research note on Wednesday, April 1st. They set an "overweight" rating and a $50.00 price target on the stock. Piper Sandler assumed coverage on Pelthos Therapeutics in a research note on Friday, February 27th. They set an "overweight" rating and a $48.00 price target on the stock. Finally, Zacks Research upgraded Pelthos Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Tuesday, March 24th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $55.80.
Check Out Our Latest Analysis on Pelthos Therapeutics
About Pelthos Therapeutics
(
Get Free Report)
We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
